NCT06134570

Brief Summary

ALDH1A1 isozyme oxidizes Retinaldehyde to retinoic acid, which regulates the expression of the genes involved in tumor-initiating stem-like cells, thereby initiating tumor growth and resistance to drugs. Much emphasis has been focused on ALDH1A1 as a CSC marker. High expression of ALDH1A1 has been reported as a poor prognostic marker in several tumor types and is associated with poor patient outcomes .

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 12, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 18, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

November 18, 2023

Status Verified

October 1, 2023

Enrollment Period

8 months

First QC Date

November 12, 2023

Last Update Submit

November 12, 2023

Conditions

Breast Cancer

Keywords

breast cancerCSCsALDH1A1

Outcome Measures

Primary Outcomes (1)

  • evaluate expression of ALDH1A1 in invasive mammary carcinoma

    immunohistochemical study

    4 month

Eligibility Criteria

Sexfemale
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

sixty paraffin blocks of breast carcinoma collected from the archive of Pathology Department of Sohag Faculty of Medicine

You may qualify if:

  • Patients with invasive mammary carcinoma carcinoma and underwent surgery

You may not qualify if:

  • Cases received pre-operative chemotherapy or radiotherapy.
  • Cases with insufficient clinical data.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine

Sohag, Egypt

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer at Pathology Department, Faculty of Medicine

Study Record Dates

First Submitted

November 12, 2023

First Posted

November 18, 2023

Study Start

October 1, 2023

Primary Completion

June 1, 2024

Study Completion

June 1, 2024

Last Updated

November 18, 2023

Record last verified: 2023-10

Locations

EG(1)